Holen Sie sich die Stockscreener-App
312.02
1.70%
-5.40
Schlusskurs vom Vortag:
$317.42
Offen:
$307.59
24-Stunden-Volumen:
428.08K
Relative Volume:
1.55
Marktkapitalisierung:
$32.37B
Einnahmen:
$5.76B
Nettoeinkommen (Verlust:
$514.49M
KGV:
69.63
EPS:
4.4813
Netto-Cashflow:
$1.10B
1W Leistung:
+4.46%
1M Leistung:
+18.78%
6M Leistung:
-7.74%
1J Leistung:
+7.46%
1-Tages-Spanne:
$303.08
$315.18
1-Wochen-Bereich:
$301.13
$323.82
52-Wochen-Spanne:
$253.95
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Firmenname
Beone Medicines Ltd Adr
Sektor
Branche
Telefon
41-616851900
Adresse
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
312.02 | 32.93B | 5.76B | 514.49M | 1.10B | 4.4813 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-09-18 | Eingeleitet | Barclays | Overweight |
| 2025-04-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-12-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-09-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-06 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-12 | Eingeleitet | Macquarie | Outperform |
| 2023-08-17 | Eingeleitet | Jefferies | Buy |
| 2023-07-17 | Eingeleitet | Citigroup | Buy |
| 2023-06-30 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Eingeleitet | Daiwa Securities | Buy |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-10-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Fortgesetzt | JP Morgan | Overweight |
| 2022-03-17 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Eingeleitet | Deutsche Bank | Buy |
| 2021-10-12 | Eingeleitet | Bernstein | Outperform |
| 2021-10-06 | Hochstufung | CLSA | Underperform → Buy |
| 2021-03-08 | Eingeleitet | China Renaissance | Buy |
| 2021-03-01 | Herabstufung | CLSA | Outperform → Underperform |
| 2020-11-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
Alle ansehen
Beone Medicines Ltd Adr Aktie (ONC) Neueste Nachrichten
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
BeOne Medicines (NASDAQ:ONC) CEO Sells 145,861 Shares of Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 11,698 Shares - MarketBeat
BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 48,520 Shares of Stock - MarketBeat
How Chemotherapy-Free Phase 3 MCL Success At BeOne Medicines (ONC) Has Changed Its Investment Story - Sahm
ONC Stock Quote Price and Forecast - CNN
Candriam S.C.A. Grows Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells 664 Shares of Stock - MarketBeat
ETFs Investing in BeOne Medicines Ltd. Sponsored ADR Stocks - TradingView
ONCBeOne Medicines Ltd ADR Options - Finviz
ONC News | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
BeOne Medicines Advances Chemotherapy-Free Lymphoma Strategy - Sahm
49BA Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of BeOne Medicines Ltd. Sponsored ADR – DUS:49BA - TradingView
A1437N Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of BeOne Medicines Ltd. Sponsored ADR – DUS:49BA - TradingView
Price to book forward of BeOne Medicines Ltd. Sponsored ADR – DUS:49BA - TradingView
Enterprise value to revenue forward of BeOne Medicines Ltd. Sponsored ADR – TURQUOISE:ONCN - TradingView
BeOne Medicines Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ONC) - TradingView
BeOne Medicines Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.04 ADR - TradingView
Price to sales forward of BeOne Medicines Ltd. Sponsored ADR – TURQUOISE:ONCN - TradingView
BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 3,410 Shares - MarketBeat
Price to book forward of BeOne Medicines Ltd. Sponsored ADR – TURQUOISE:ONCN - TradingView
Enterprise value to EBITDA forward of BeOne Medicines Ltd. Sponsored ADR – TURQUOISE:ONCN - TradingView
BeOne Medicines (NASDAQ:ONC) Insider Sells $295,558.32 in Stock - MarketBeat
Temasek Holdings Private Ltd Sells 91,877 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Barings LLC Reduces Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Here's How Much You Would Have Made Owning BeOne Medicines Stock In The Last 10 Years - Sahm
A Look At BeOne Medicines (ONC) Valuation After Analyst Upgrades And Positive ASCO 2026 Clinical Updates - Sahm
Capital International Sarl Raises Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Is BeOne Medicines (ONC) Quietly Recasting Its Hematology Roots Into a Multi-Franchise Oncology Platform? - Sahm
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3 - sharewise.com
《AI》BEONE MEDICINES(06160.HK) Displays Technical Pattern of Range Breakout - AASTOCKS.com
《AI》BEONE MEDICINES(06160.HK) Displays Technical Pattern of Triangle Breakout - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 5.1M shares at $176.8, $901.68M turnover - AASTOCKS.com
BEONE MEDICINES (06160.HK) An Taisite Approved in Mainland China for Second-line Treatment of Small Cell Lung Cancer - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 254.9K shares at $175.1, $44.633M turnover - AASTOCKS.com
CICC: Focus on Positive Capital Flow Impact from Index Review on BEONE MEDICINES (06160.HK), J&T EXPRESS-W (01519.HK), KNOWLEDGE ATLAS (02513.HK) and MINIMAX-W (00100.HK) - AASTOCKS.com
Marriott Upgraded, Roku Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Bearish block trade of BEONE MEDICINES(06160) 231.3K shares at $185.8, $42.976M turnover - AASTOCKS.com
BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative - Sahm
HSI To Add J&T EXPRESS-W (01519.HK), CHALCO (02600.HK), BEONE MEDICINES (06160.HK) after Quarterly Review - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 212K shares at $184.5, $39.114M turnover - AASTOCKS.com
ONC Stock Price, Quote & Chart | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
BeOne Medicines Ltd.: BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts - FinanzNachrichten.de
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts - Via TT
Bearish block trade of BEONE MEDICINES(06160) 323.6K shares at $183.1, $59.251M turnover - AASTOCKS.com
Bearish block trade of BEONE MEDICINES(06160) 206.1K shares at $175.1, $36.088M turnover - AASTOCKS.com
Finanzdaten der Beone Medicines Ltd Adr-Aktie (ONC)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.54%
3.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):